Continued good compliance in Stayble Therapeutics´ Phase IIb study
Stayble Therapeutics AB ("Stayble" or the "Company") provides an update on the ongoing Phase IIb study. The company sees continued good compliance and approx. 70% of all patients have completed their 6-month follow-up, which is the primary endpoint of the study. Furthermore, Stayble is following the development in Russia and the assessment is that patients can conduct their follow-up visits without any difficulties.
As previously reported, Stayble recently reached the important milestone of enrolling the last patient in the Phase IIb study. After the treatment, patients will return to the clinic for a follow-up after 1, 3, 6 and 12 months. Approximately 70% of patients have completed their 6-month visit to this date which is the most crucial visit in the study. Furthermore, Stayble continues to see a low dropout rate of patients as only four patients have left the study, two of which after the 6-month visit, thus not affecting the results.
The implementation of the follow-up phase is going well in all countries, including Spain, the Netherlands and Russia. The situation in Russia is being monitored particularly closely to ensure patient safety and the continued high quality of the study. For clinical research, there are no restrictions of working with foreign companies from any country, and therefore there are no obstacles for the Company's Clinical Contract Research Organization (CRO), to collect data, write the report, or transfer all collected data to Stayble.
With continued high quality, adherence, engaged clinicians and collaborators, Stayble looks forward to presenting top-line data from the study in Q4 2023.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
Mail: andreas.gerward@stayble.se
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail ca@skmg.se